Chemomab Therapeutics Ltd. · NASDAQ:CMMB
Chemomab Therapeutics — Anchiano Therapeutics — Global Life Sciences Conference March 9-10, 2021
21 slides from Chemomab Therapeutics's conference presentation, Mar 9, 2021
Slide 1: Pioneering Innovative Treatments for Fibrotic Diseases
Pioneering Innovative Treatments Corporate Overview | Non-Confidential for Fibrotic Diseases Global Life Sciences March 9-10, 2021 Conference
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among other things, statements regarding the clinical development pathway for CM-101; the proposed merger b
Slide 3: Chemomab Highlights
Chemomab Highlights A Clinical Stage Biotech Company Focus • Development of innovative therapies for rare fibrotic diseases • • • CM-101, a first-in-class CCL24 neutralizing mAb with confirmed anti-fibrotic MoA Validated CCL24 as critical fibrosis target: clinical findings and experimental models Po
Slide 4: Experienced Leadership
Experienced Leadership ADI MOR, PhD Chief Executive Officer, Co-Founder ARNON AHARON, MD Chief Medical Officer SIGAL FATTAL, CPA Chief Financial Officer SHARON ELKOBI, MSc, MBA VP Business Development MICHAL SEGAL-SALTO, PhD VP Research and Development SHARON HASHMUELI, PhD Head of CMC and Regulator
Slide 5: CCL24 is a Novel Therapeutic Target for Fibrosis
CCL24 is a Novel Therapeutic Target for Fibrosis Critical Mediator Promoting Inflammation and Fibrosis CCL24-secreting cells M2 Macrophages, Immune and Epithelial cells CCL24 Dual role in promoting fibrosis - directly activates fibroblasts - enhances local immune cell recruitment CCL24-regulated cel
Slide 6: CM-101 - A First in Class mAb Blocking CCL24
CM-101-A First in Class mAb Blocking CCL24 Dual Mechanism of Action Interfering with the Core Fibrotic Pathways CM-101 CCL24 Inflamm brosis Immune cells recruitment Fibroblasts activation & proliferation CoM - Composition of Matter 6 ation CCR3 Fi
Slide 7: Primary Sclerosing Cholangitis (PSC)
Primary Sclerosing Cholangitis (PSC) ~70K PSC Patients in 7MM; >$1B market value A rare, chronic bile duct inflammatory and fibrotic disease o leading to end-stage liver disease and cirrhosis Median Survival of 10-12 years with no intervention PSC patients have 40-fold increased risk of liver cancer
Slide 8: CCL24 Plays a Key Role in PSC Pathology
CCL24 Plays a Key Role in PSC Pathology CCL24 expression is significantly and selectively elevated in PSC livers Strong correlation between CCL24 and fibrotic biomarkers CCL24 level in healthy vs PSC patients' livers tissues CCL24 serum level in PSC patients Healthy Liver PSC Liver Cholangiocytes Im
Slide 9: CM-101 Reduces Liver Fibrosis by 80%
CM-101 Reduces Liver Fibrosis by 80% Reduced Liver Collagen in TAA Liver Fibrosis Rat Model Using Therapeutic Design SIRIUS RED (COLLAGEN) 82% reduction Col1A1 Col3A1 TIMP1 ACTA2 TGF-β 100 Pro-fibrotic genes 80 60 40 ALT AST ALP Liver enzymes 20 0 TAA TAA +CM-101 (2.5mg/kg) Segal-Salto et al, JHEP r
Slide 10: CM-101 Reduces Liver Injury and Fibrosis in PSC
CM-101 Reduces Liver Injury and Fibrosis in PSC Cholestasis, Inflammation and fibrosis are reduced in the MDR2 Knockout Model in Mice CM-101 Interferes with the core mechanisms of PSC: • • • • • Alkaline Phosphatase Bile acid Liver collagen levels Circulating and tissue resident Inflammatory cells C
Slide 11: Systemic Sclerosis (SSc)
Systemic Sclerosis (SSc) ~140K SSc patients in 7MM ; >$1B market value Rare autoimmune rheumatic disease characterized by inflammation and fibrosis of the skin and internal organs as well as vasculopathy Age at diagnosis is 30-50 years More prevalent in women (3:1) SSc has the highest mortality rate
Slide 12: CCL24: a Critical Node Potentiating Systemic Sclerosis
CCL24: a Critical Node Potentiating Systemic Sclerosis CCL24 is significantly overexpress in SSc skin CCL24 is elevated in SSc serum and correlates with disease progression CCL24 level in SSc patients’ serum CCL24 level in SSc patients’ skin vs. healthy Healthy Skin SSc Skin *** Collaboration with U
Slide 13: CCL24 Blockade is Singularly Sufficient to Attenuate Fibrosis
CCL24 Blockade is Singularly Sufficient to Attenuate Fibrosis Knocking out the CCL24 gene attenuates bleomycin Induced (SSc) model Immune cell lung infiltration Dermal thickness 1.8 5000 1.6 4000 1.4 3000 1.2 2000 1 1000 0.8 0.6 0 WT-BLM WT PBS WT BLM CCL24 KO-CCL24 KO-CCL24 KO-BLM CCL24 KO-BLM CCL2
Slide 14: CM-101 Profoundly Reduces Skin and Lung Fibrosis in SSc Models
CM-101 Profoundly Reduces Skin and Lung Fibrosis in SSc Experimental Models Relevant to Systemic Sclerosis Using Prevention and Therapeutic Designs Bleomycin (SC) induced dermal fibrosis 100 ** 80 Attenuates skin and lung fibrosis levels in bleomycin induced models using treatment mode 60 40 20 0 Ve
Slide 15: CM-101 Holds a Robust Preclinical Package
CM-101 Holds a Robust Preclinical Package Significantly Attenuates Fibrosis CCL24 Target Validation Ex-Vivo (Patient Samples) PSC • Biomarkers correlation • Overexpression of CCL24 and CCR3 Systemic Sclerosis & Inflammation Across a Wide Range of Models Mechanism of Action CM-101 effects on fibrobla
Slide 16: CM-101 is Safe & Well Tolerated
CM-101 is Safe & Well Tolerated Phase 1a Single Administration study in Healthy Volunteers • CM-101 was safe and well tolerated at all tested doses up to 10 mg/kg and for both formulations • Average t1/2 of 19-21 days (for IV and SC), supports long interval administration once every 2-4 weeks • Dose
Slide 17: Ph1b Demonstrates Safety & Tolerability
Ph1b Demonstrates Safety & Tolerability Along 15 Weeks Treatment Phase 1b Multiple Administration Study in NAFLD Patients • Study population-NAFLD patients with normal liver function Double-Blind, Randomized Escalating Dose (N=16) • Multiple CM-101 administrations were safe and well tolerated using
Slide 18: CM-101 Target Engagement & Anti-Fibrotic Mechanism
CM-101 Target Engagement & Anti-Fibrotic Mechanism Human Confirmation for CM-101 Anti-Fibrotic Mechanism of Action Biomarkers* Elastography PK-PD Fibrotic 30 20 10 250 60 200 15 10 0 40 150 0 0 100 20 -10 -10 -15 50 0 0 -20 -20 -30 0 21 42 63 84 105 EOT 126 ProC4 Nordic Biosciences , Denmark TIMP1 F
Slide 19: CM-101 Clinical Development Plan and Key Catalysts
CM-101 Clinical Development Plan and Key Catalysts Phase 2 Studies Driving Pivotal Studies Primary Sclerosing Cholangitis (IV formulation) Phase 2: 12 wk treatment *Randomized placebo-controlled; Europe and Israel study sites LPI Q4/21 FPI Q4/20 IA POC Phase 2: 24 wk treatment Randomized placebo-con
Slide 20: Chemomab, Fighting Fibrosis Across Indications
Chemomab, Fighting Fibrosis Across Indications Opportunity CM-101 ▪ Clinical stage company entering Ph2 trials in multiple fibrotic indications with high unmet need Substantial value inflection points in 2021-2022 Strong leadership with proven track record ▪ ▪ First-in-class mAb blocking CCL24 Novel
Slide 21: Thank You
Thank You Presentation name
Anchiano Therapeutics — Global Life Sciences Conference March 9-10, 2021 on 6ix